

Korea lays focus on digital therapy services for neuropsychiatric disorders

15 June 2021 | News

KT and NeuroSigma partner to jointly develop and commercialize neuroelectronic ADHD therapies inside and outside of Korea



Korea's largest telecommunications service provider KT Corp has signed a memorandum of understanding with NeuroSigma, Inc., forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including Attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.

NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, and is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD.

In addition, NeuroSigma plans to conduct additional trials for label expansion of the Monarch eTNS System in ADHD and pivotal trials for depression and epilepsy.

Through this partnership with NeuroSigma, KT will support the design and development of next-generation versions of eTNS products incorporating artificial intelligence (AI), big data, and cloud capabilities; advanced monitoring and AI analysis services, provided through KT's digital healthcare platform; and commercialization and manufacturing partnerships in Korea.

Kim Hyung-wook, KT's Head of Future Value Promotion Office, said, "In Korea, digital therapy is still in its infancy, but its utility and growth potential are excellent. Starting with our strategic partnership with NeuroSigma, we will actively foster and promote digital therapeutics, including electronic drugs, as the basis of new and innovative healthcare businesses and to expand the digital therapeutics market in Korea and beyond."